Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Oncology  |  Family Medicine

Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

Cancer Prevention Clinical Trials

A listing of Cancer Prevention medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (26) clinical trials

Multicentre International STudy for the Prevention With Ialuril of Radio-induced Cystitis (MISTIC)

Radiotherapy will last for 6 weeks. During planning of treatment, regimen and average dose to the whole bladder will be recorded to assess the impact of EBRT on urinary symptoms. The treated-group will receive also intravesical Ialuril weekly for 6 weeks (in the 24 hours before every radiation therapy weekly ...

Phase

Memantine for Prevention of Cognitive Late Effects in Pediatric Patients Receiving Cranial Radiation Therapy for Localized Brain Tumors

Participants will be randomized to take part in one of two groups: The Memantine Group will be prescribed memantine at a dosage following FDA-approved adult labeling. A low dose will initially be given beginning at least two weeks ( 7 days) prior to beginning radiation therapy. The dose will increase ...

Phase

Supersaturated Calcium Phosphate Oral Rinse (Caphosol ) For the Prevention of Oral Mucositis in Children Undergoing Chemotherapeutic Treatments

The study will be a double-blinded study so that the researchers or research nurses and the patients/parents are unaware of the solution used (Caphosol vs 0.9% NaCl). They both taste very similar and are packaged to ampules similar to each other. Since Caphosol consists of two solutions (A and B) ...

Phase

Phase II Study of Metformin for Reduction of Obesity-Associated Breast Cancer Risk

High adiposity is a major risk factor for a number of chronic diseases, including type 2 diabetes, cardiovascular diseases, and certain types of cancer, including postmenopausal breast cancer. The increased postmenopausal breast cancer risk in women with high adiposity is likely to be attributed to multiple metabolic disturbances including altered ...

Phase

To Evaluate the Effect of MCS in Prostate Cancer Prevention

To evaluate the effect of MCS compared with placebo in reducing the risk of biopsy-detectable prostate cancer in high-risk subjects after 104 weeks (24 months) of treatment.

Phase

Tertiary Prevention of Head and Neck Cancer With a Dietary Intervention

Patients deemed to be in complete remission at month 3 (+/- 1 month) after curative treatment will be considered for this trial. At each follow up visit the patients will state all the changes and new symptoms they experienced and they will receive both physical and fiberoptic endoscopic head and ...

Phase

Panitumumab Skin Toxicity Prevention Trial

Background and rationale: EGFR represents the main and more studied signal activation pathway in the development of colorectal carcinoma. KRAS, NRAS, BRAF and PI3KA mutations and ERBB2 and MET amplification are responsible for most of the cases of primary resistance to anti-EGFR antibody treatments. Despite the identification of these resistance ...

Phase

Aging Mammary Stem Cells and Breast Cancer Prevention

A non-randomized, open-label, phase II, window of opportunity trial will be carried out to see if a 5-7 day rapamycin treatment can reduce malignant markers and aberrant MaSC number

Phase

Vaccine Therapy in Preventing Human Papillomavirus Infection in Younger Cancer Survivors

PRIMARY OBJECTIVES: I. Using a cross-sectional survey approach, estimate the prevalence of HPV vaccine non-initiation: a) Examine sociodemographic, behavioral, and medical determinants of HPV vaccine non-initiation. II. Using a single-arm, phase II, open-label, prospective longitudinal trial design, to evaluate the 3-dose HPV quadrivalent (HPV4) and nonavalent (HPV9) vaccine series and ...

Phase

Mesalamine for Colorectal Cancer Prevention Program in Lynch Syndrome

This is a multicenter, multinational, randomized, 3-arm, double-blind, phase II clinical study with 2400mg Mesalamine, 1200mg Mesalamine or placebo in LS patients for a 2-year treatment. 540 tumor free carriers of a known genetic mutation in a major MMR gene (including patients in which the polyps are endoscopically removed) will ...

Phase